Cryofocus Biotechnology Co., Ltd (HKG: 6922), a Shanghai-based specialist in cryoablation treatment, has announced a strategic distribution agreement with the Shanghai subsidiary of US medical device giant Boston Scientific Corporation (NYSE: BSX).
As per the terms of the agreement, Cryofocus is set to become the exclusive marketing partner and sales agent for Boston Scientific’s respiratory intervention products throughout mainland China. The collaboration will leverage the combined strengths of both companies to facilitate the commercialization of these products. Financial details of the agreement were not disclosed.- Flcube.com
